한빛사논문
Shivani Handa 1, Jeong-Ok Lee 2, Andriy Derkach 3, Richard M Stone 4, Alan Saven 5, Jessica K Altman 6, Michael Rhodes Grever 7, Kanti R Rai 8, Madhulika Shukla 3, Shreya Vemuri 3, Skye Montoya 9, Justin Taylor 9, Omar Abdel-Wahab 10, Martin S Tallman 11, Jae H Park 11
1Icahn School of Medicine at Mount Sinai, New York, New York, United States.
2Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of.
3Memorial Sloan-Kettering Cancer Center, New York, New York, United States.
4Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
5Scripps Clinic, La Jolla, California, United States.
6Northwestern University, Chicago, Illinois, United States.
7Ohio State University, Colmubus, Ohio, United States.
8Cancer Institute at Zucker School of Medicine Hofstra-Northwell, United States.
9University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States.
10Memorial Sloan Kettering Cancer Center, New York, New York, United States.
11Weill Cornell Medical College, United States.
Corresponding Author; Jae H Park
Abstract
Hairy cell leukemia (HCL) is a rare chronic B cell lymphoproliferative disorder characterized by high prevalence of BRAF V600E mutation.1,2 Purine nucleoside analogues can achieve an overall response rate (ORR) of 90 to 100% and complete responses (CR) of 80 to 95% and remain the mainstay of first-line treatment in HCL.3,4 However, approximately 30-40% patients will experience recurrent disease and relapse-free survival rates decrease with repeated courses of purine analogue-based treatments with cumulative myelotoxicity and immune suppression.5,6 The genetic basis of HCL was first uncovered a decade ago when Tiacci and colleagues reported that BRAF V600E is a key mutation in HCL,7 a finding that was further validated by subsequent studies.8,9 Based on these findings, we conducted a multicenter phase 2 clinical trial in the U.S. evaluating the efficacy and safety of vemurafenib, an oral BRAF inhibitor, in patients with relapsed/ refractory (R/R) HCL. We previously published the initial outcome of 26 U.S. patients together with the Italian study conducted by Tiacci et al.7 Vemurafenib monotherapy induced 96-100% ORR and 35-42% CR rates in both studies. With a median follow-up duration of 11.7 months, we observed relapses in 29% of the patients but the long-term clinical outcome and response or acquired resistance to vemurafenib retreatment have not been previously reported. Herein, we report the long-term follow-up data of the entire patient cohort in the completed U.S. clinical trial (NCT01711632) including the ORR, relapse free survival, clinical factors associated with improved survival as well as outcomes after retreatment with vemurafenib or alternative agents.
논문정보
관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기